Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer.

Kaplan–Meier analysis, comparing patients with these mutations who received ICI therapy to those who did not, indicated a trend toward improved PFS ( p = 0.38) and OS ( p = 0.38) in the ICI‐treated group, although the difference did not reach statistical significance due to the limited sample size (Figure 4B ).

also in 111,027 other papers